 SAN DIEGO, Sept. 20, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief Executive Officer CEO, effective immediately. 